0.737  -0.063 (-7.88%)		05-04 12:16
Open: 0.7501 High: 0.7548 Volume: 20,793		Pre. Close: 0.8 Low: 0.69 Market Cap: 0(M)

Short term
Mid term
Targets	6-month :	1.2	1-year :	1.49
Resists	First :	1.02	Second :	1.27
Pivot price	0.77
Supports	First :	0.61	Second :	0.51
MAs	MA(5) :	0.82	MA(20) :	0.75
	MA(100) :	2.23	MA(250) :	4.85
MACD	MACD :	-0.1	Signal :	-0.2
%K %D	K(14,3) :	22.8	D(3) :	33.4
RSI	RSI(14): 40.1
52-week	High :	15.89	Low :	0.61

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ GCTK ] has closed above bottom band by 26.6%. Bollinger Bands are 81.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.84 - 0.85	0.85 - 0.85
Low:	0.75 - 0.76	0.76 - 0.76
Close:	0.79 - 0.8	0.8 - 0.81

GlucoTrack, Inc., a medical device company, designs, develops, and commercializes non-invasive glucose monitoring devices for use by people suffering from diabetes and pre-diabetics in Israel and internationally. It develops GlucoTrack glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.

Fri, 01 May 2026
[EFFECT] Glucotrack, Inc. SEC Filing - Stock Titan

Thu, 30 Apr 2026
Glucotrack (NASDAQ: GCTK) swaps $988K debt for 1.3M new shares - Stock Titan

Thu, 30 Apr 2026
Peer-reviewed CBGM data back Glucotrack (NASDAQ: GCTK) IDE plans - Stock Titan

Thu, 30 Apr 2026
An implantable glucose monitor held accuracy for 240 days in animal study - Stock Titan

Thu, 30 Apr 2026
Glucotrack Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability of Continuous Blood Glucose Monitoring Technology - The Globe and Mail

Wed, 29 Apr 2026
GCTK Stock Chops Higher As GlucoTrack Marks Key CGM Milestones - StocksToTrade

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	4 (M)
Shares Float	2 (M)
Held by Insiders	3 (%)
Held by Institutions	8.9 (%)
Shares Short	670 (K)
Shares Short P.Month	43 (K)

EPS	-31.22
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.1
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-146.1 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-4.39
Qtrly Earnings Growth	0 %
Operating Cash Flow	-15 (M)
Levered Free Cash Flow	-9 (M)

PE Ratio	-0.03
PEG Ratio	0
Price to Book value	0.23
Price to Sales	0
Price to Cash Flow	-0.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.